Hepatic porphyria is a type of porphyria that affects the liver. It's caused by a missing enzyme in the liver that's needed to make heme. This leads to a buildup of a substance called porphyrin, which can cause skin problems and other symptoms.
Every report comes from a Lived member, sent anonymously.
Have you tried Hemin for Hepatic Porphyria?
Hepatic porphyria is a group of rare disorders in which the liver cannot complete the chain of steps it uses to make heme, a molecule the body needs for blood and for many enzymes. When one step in that chain is weak, the building blocks made earlier (porphyrins and their precursors) pile up and cause illness. Which building block accumulates shapes the kind of illness a person has. The acute hepatic porphyrias, of which acute intermittent porphyria is the most common, affect the nervous system. They cause attacks that build over hours or days and can last days or weeks. The hallmark is severe pain, usually in the abdomen but sometimes in the back or limbs, often with nausea, vomiting, constipation, a racing heart and anxiety. Urine may look dark or reddish. Severe attacks can affect the nerves that control muscles and breathing, and can cause seizures. Two acute types, variegate porphyria and hereditary coproporphyria, can also blister sun-exposed skin. Porphyria cutanea tarda, the most common porphyria overall, affects only the skin. Blisters, fragile skin that tears easily and heals slowly, scarring and color changes develop on areas exposed to sunlight. Because the acute forms usually cause no symptoms between attacks, and their pain can look like many common abdominal problems, diagnosis is often delayed by years.
The acute hepatic porphyrias are inherited. A person usually carries one altered copy of a gene for a heme-making enzyme, passed down from one parent. Carrying the variant is not the same as having the disease: only a small minority of carriers ever have an attack. Attacks happen when something pushes the liver to make more heme than the weakened pathway can handle. Known triggers include certain medicines (some seizure medicines, antibiotics, anesthetics and hormonal birth control among them), alcohol, smoking, fasting or sharply cutting carbohydrates, infection or other illness, and physical or emotional stress. The hormone progesterone is an important trigger. That is one reason about 90% of people with symptoms are women, and why attacks mostly occur between the teenage years and menopause, sometimes in step with the menstrual cycle. Some attacks have no identifiable trigger. Porphyria cutanea tarda is usually acquired rather than inherited, though an inherited variant sometimes contributes. It develops when a liver enzyme is blocked, most often in the setting of excess iron. Contributors include iron overload (sometimes from hemochromatosis gene variants), heavy alcohol use, smoking, hepatitis C, HIV and estrogen, such as in birth control pills or hormone therapy. It usually appears after age 40.
For the acute forms, the key first test is a single urine sample checked for two porphyrin precursors: delta-aminolevulinic acid (ALA) and porphobilinogen (PBG). During an attack both are usually at least five times the upper limit of normal, so a clearly raised PBG points strongly to acute porphyria. If ALA and PBG are normal when typical symptoms are present, porphyria is very unlikely to be the cause. Results are adjusted for creatinine to account for how concentrated the urine is. Testing is most informative during or soon after symptoms, because levels can fall back to normal between attacks, particularly in variegate porphyria and hereditary coproporphyria. A urine porphyrin test on its own is not enough: mild porphyrin elevations occur in many other conditions and often lead to a mistaken diagnosis. Once the urine tests are positive, genetic testing confirms which type is present. When a family's gene variant is known, parents, siblings and children can be tested. Most relatives who carry it will never have an attack, but knowing lets them avoid triggers and helps doctors recognize an attack quickly. Porphyria cutanea tarda is diagnosed with blood and urine porphyrin tests that show a characteristic pattern. The assessment also looks for contributors such as excess iron or hepatitis C, because addressing them is part of treatment. A skin biopsy can help rule out other blistering conditions but cannot confirm the diagnosis on its own.
Treatment depends on which type of hepatic porphyria a person has. For an acute attack, the first steps are stopping any medicine or other trigger that may have set it off and giving sugar (glucose), by mouth or through a vein, because carbohydrate dampens the liver's drive to make heme. Attacks severe enough for hospital care are treated with hemin (Panhematin), a form of heme given into a vein once a day, typically for about four days. Hemin signals the liver to stop overproducing the harmful precursors, and symptoms usually begin to ease within two to three days. Starting it early matters: hemin can halt an attack but cannot repair nerve damage that has already happened. Hospital care also treats pain and vomiting with medicines that are safe in porphyria, and corrects low sodium and other blood salt problems that attacks can cause. A small share of people, roughly 3 to 5 in 100 of those with symptoms, have frequent attacks (four or more a year). For them, doctors may consider preventive treatment. Givosiran (Givlaari) is a monthly injection under the skin, approved in the US for adults, that blocks the liver's instructions for making the enzyme that drives precursor overproduction. In the main trial it cut attacks by about 70% compared with a placebo. It requires regular blood tests, monthly at first, because it can raise liver enzymes and affect kidney function; nausea and injection-site reactions are common. Experts advise against it during pregnancy or when planning one. Regularly scheduled hemin infusions are another preventive option, though their preventive benefit is less established and repeated use can cause iron overload and require a long-term IV line. Hormone-suppressing treatment is sometimes tried for attacks tied to the menstrual cycle, with limited success. A liver transplant cures acute hepatic porphyria and is reserved for people whose severe attacks continue despite other treatment. Porphyria cutanea tarda is treated by lowering iron in the body. The usual approach is phlebotomy: drawing about a pint of blood every two weeks until iron levels fall, with blood tests to track progress. Low-dose hydroxychloroquine, an antimalarial medicine, is an effective alternative for some people. Stopping alcohol and smoking, treating hepatitis C and avoiding estrogen where possible help the disease go into remission and stay there. Sun protection matters until porphyrin levels return to normal.
Most people with an acute hepatic porphyria have only one or a few attacks in their lifetime. Attacks treated early generally resolve, though recovery from nerve-related weakness can take much longer than recovery from pain. Daily life involves a few lasting habits: checking every new prescription, over-the-counter medicine or supplement against a porphyria drug-safety list, eating regular meals with enough carbohydrate, avoiding crash diets and fasting, limiting alcohol and not smoking. Telling every clinician, dentist and anesthesia team about the diagnosis helps avoid unsafe medicines. People with recurrent attacks often carry a heavier load. In a large study, about two in three reported ongoing symptoms between attacks, most often pain, fatigue, nausea or anxiety, and nerve damage is common. Preventive treatment aims to reduce both the attacks and this day-to-day burden. Acute hepatic porphyria also brings long-term risks: high blood pressure, chronic kidney disease and liver cancer, which can develop even without cirrhosis and even in people with mild disease. Follow-up therefore includes regular, usually yearly, blood tests of liver and kidney function and blood pressure checks, and from age 50 a liver ultrasound every six months to catch cancer early. Porphyria cutanea tarda usually responds well. With treatment, most people reach remission, meaning sunlight no longer causes blisters and porphyrin levels are normal, though scars may remain. Staying away from its risk factors helps keep it in remission. Because it can damage the liver and raise the risk of cirrhosis and liver cancer, liver monitoring is part of long-term follow-up.
Ask about testing for porphyria if you have repeated episodes of severe abdominal pain with no clear cause after a standard workup, particularly as a woman between about 15 and 50, or if blisters and fragile skin keep appearing on sun-exposed areas. If a relative has been diagnosed, ask whether genetic testing makes sense for you. If you have a known acute porphyria, contact your care team right away when the familiar pain of an attack begins, since early treatment works best. Severe pain that does not settle, persistent vomiting, new muscle weakness, confusion or hallucinations, a seizure or trouble breathing needs emergency care; tell the team you have acute porphyria so they can consider hemin and avoid unsafe medicines.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Hepatic Porphyria is like, what's helped you, or ask the community a question.